Search

Your search keyword '"Berg, David D."' showing total 355 results
Start Over Author "Berg, David D."
355 results on '"Berg, David D."'

1. Continuum of Preshock to Classic Cardiogenic Shock in the Critical Care Cardiology Trials Network Registry

Author

Patel, Siddharth M., Berg, David D., Bohula, Erin A., Baird-Zars, Vivian M., Park, Jeong-Gun, Barnett, Christopher F., Daniels, Lori B., Fordyce, Christopher B., Ghafghazi, Shahab, Goldfarb, Michael J., Gorder, Kari, Kwon, Younghoon, Leibner, Evan, Menon, Venu, Potter, Brian J., Prasad, Rajnish, Solomon, Michael A., Teuteberg, Jeffrey J., Thompson, Andrea D., Zakaria, Sammy, Katz, Jason N., van Diepen, Sean, and Morrow, David A.

Published
2024
Full Text
View/download PDF

2. Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network Registry

Author

Patel, Siddharth M., Berg, David D., Bohula, Erin A., Baird-Zars, Vivian M., Barsness, Gregory W., Chaudhry, Sunit-Preet, Chonde, Meshe D., Cooper, Howard A., Ginder, Curtis, Jentzer, Jacob C., Kontos, Michael C., Miller, P. Elliott, Newby, L. Kristin, O’Brien, Connor G., Park, Jeong-Gun, Pierce, Matthew J., Pisani, Barbara A., Potter, Brian J., Shah, Kevin S., Teuteberg, Jeffrey J., Katz, Jason N., van Diepen, Sean, and Morrow, David A.

Published
2024
Full Text
View/download PDF

3. Prognostic performance of the IABP-SHOCK II Risk Score among cardiogenic shock subtypes in the critical care cardiology trials network registry

Author

Alviar, Carlos L., Li, Boyangzi K., Keller, Norma M., Bohula-May, Erin, Barnett, Christopher, Berg, David D., Burke, James A., Chaudhry, Sunit-Preet, Daniels, Lori B., DeFilippis, Andrew P., Gerber, Daniel, Horowitz, James, Jentzer, Jacob C., Katrapati, Praneeth, Keeley, Ellen, Lawler, Patrick R., Park, Jeong-Gun, Sinha, Shashank S., Snell, Jeffrey, Solomon, Michael A., Teuteberg, Jeffrey, Katz, Jason N., van Diepen, Sean, and Morrow, David A.

Published
2024
Full Text
View/download PDF

5. Pulmonary Artery Catheter Use and Mortality in the Cardiac Intensive Care Unit

Author

Kadosh, Bernard S., Berg, David D., Bohula, Erin A., Park, Jeong-Gun, Baird-Zars, Vivian M., Alviar, Carlos, Alzate, James, Barnett, Christopher F., Barsness, Gregory W., Burke, James, Chaudhry, Sunit-Preet, Daniels, Lori B., DeFilippis, Andrew, Delicce, Anthony, Fordyce, Christopher B., Ghafghazi, Shahab, Gidwani, Umesh, Goldfarb, Michael, Katz, Jason N., Keeley, Ellen C., Kenigsberg, Benjamin, Kontos, Michael C., Lawler, Patrick R., Leibner, Evan, Menon, Venu, Metkus, Thomas S., Miller, P. Elliott, O’Brien, Connor G., Papolos, Alexander I., Prasad, Rajnish, Shah, Kevin S., Sinha, Shashank S., Snell, R. Jeffrey, So, Derek, Solomon, Michael A., Ternus, Bradley W., Teuteberg, Jeffrey J., Toole, Joseph, van Diepen, Sean, Morrow, David A., and Roswell, Robert O.

Published
2023
Full Text
View/download PDF

7. Presentation and Outcomes of Patients With Preoperative Critical Illness Undergoing Cardiac Surgery

Author

Metkus, Thomas S., Alviar, Carlos L., Baird-Zars, Vivian M., Barsness, Gregory W., Berg, David D., Bohula, Erin A., Burke, James A., Fordyce, Christopher B., Guo, Jianping, Katz, Jason N., Keeley, Ellen C., Menon, Venu, Miller, P. Elliott, O'Brien, Connor G., Sinha, Shashank S., So, Derek, Ternus, Bradley W., Vadhar, Sagar, van Diepen, Sean, and Morrow, David A.

Published
2023
Full Text
View/download PDF

10. Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy.

Author

Moura, Filipe A., Bellavia, Andrea, Berg, David D., Melloni, Giorgio E. M., Feinberg, Mark W., Leiter, Lawrence A., Bohula, Erin A., Morrow, David A., Scirica, Benjamin A., Wiviott, Stephen D., and Sabatine, Marc S.

Subjects
TYPE 2 diabetes, INDIVIDUALIZED medicine, ANTIOBESITY agents, BODY mass index, WEIGHT loss
Abstract

Aims: To develop a clinical risk model to identify individuals at higher risk of developing new‐onset diabetes and who might benefit more from weight loss pharmacotherapy. Materials and Methods: A total of 21 143 patients without type 2 diabetes at baseline from two TIMI clinical trials of stable cardiovascular patients were divided into a derivation (~2/3) and validation (~1/3) cohort. The primary outcome was new‐onset diabetes. Twenty‐seven candidate risk variables were considered, and variable selection was performed using multivariable Cox regression. The final model was evaluated for discrimination and calibration, and for its ability to identify patients who experienced a larger benefit from the weight loss medication lorcaserin in terms of risk of new‐onset diabetes. Results: During a median (interquartile range) follow‐up of 2.3 (1.8–2.7) years, new‐onset diabetes occurred in 1013 patients (7.7%). The final model included five independent predictors (glycated haemoglobin, fasting glucose, age, body mass index, and triglycerides/high‐density lipoprotein). The clinical risk model showed good discrimination (Harrell's C‐indices 0.802, 95% confidence interval [CI] 0.788–0.817 and 0.807, 95% CI 0.788–0.826) in the derivation and validation cohorts. The calibration plot demonstrated adequate calibration (2.5‐year area under the curve was 81.2 [79.1–83.5]). While hazard ratios for new‐onset diabetes with a weight‐loss therapy were comparable across risk groups (annual risks of <1%, 1%–5%, and >5%), there was a sixfold gradient in absolute risk reduction from lowest to highest risk group (p = 0.027). Conclusions: The developed clinical risk model effectively predicts new‐onset diabetes, with potential implications for personalized patient care and therapeutic decision making. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Sex Differences in Characteristics, Resource Utilization, and Outcomes of Cardiogenic Shock: Data From the Critical Care Cardiology Trials Network (CCCTN) Registry.

Author

Daniels, Lori B., Phreaner, Nicholas, Berg, David D., Bohula, Erin A., Chaudhry, Sunit-Preet, Fordyce, Christopher B., Goldfarb, Michael J., Katz, Jason N., Kenigsberg, Benjamin B., Lawler, Patrick R., Correa, Miguel A. Martillo, Papolos, Alexander I., Roswell, Robert O., Sinha, Shashank S., van Diepen, Sean, Jeong-Gun Park, and Morrow, David A.

Abstract

BACKGROUND: Sex disparities exist in the management and outcomes of various cardiovascular diseases. However, little is known about sex differences in cardiogenic shock (CS). We sought to assess sex-related differences in the characteristics, resource utilization, and outcomes of patients with CS. METHODS: The Critical Care Cardiology Trials Network is a multicenter registry of advanced cardiac intensive care units (CICUs) in North America. Between 2018 and 2022, each center (N=35) contributed annual 2-month snapshots of consecutive CICU admissions. Patients with CS were stratified as either CS after acute myocardial infarction or heart failure-related CS (HF-CS). Multivariable logistic regression was used for analyses. RESULTS: Of the 22 869 admissions in the overall population, 4505 (20%) had CS. Among 3923 patients with CS due to ventricular failure (32% female), 1235 (31%) had CS after acute myocardial infarction and 2688 (69%) had HF-CS. Median sequential organ failure assessment scores did not differ by sex. Women with HF-CS had shorter CICU lengths of stay (4.5 versus 5.4 days; P<0.0001) and shorter overall lengths of hospital stay (10.9 versus 12.8 days; P<0.0001) than men. Women with HF-CS were less likely to receive pulmonary artery catheters (50% versus 55%; P<0.01) and mechanical circulatory support (26% versus 34%; P<0.0001) compared with men. Women with HF-CS had higher in-hospital mortality than men, even after adjusting for age, illness severity, and comorbidities (34% versus 23%; odds ratio, 1.76 [95% CI, 1.42-2.17]). In contrast, there were no significant sex differences in utilization of advanced CICU monitoring and interventions, or mortality, among patients with CS after acute myocardial infarction. CONCLUSIONS: Women with HF-CS had lower use of pulmonary artery catheters and mechanical circulatory support, shorter CICU lengths of stay, and higher in-hospital mortality than men, even after accounting for age, illness severity, and comorbidities. These data highlight the need to identify underlying reasons driving the differences in treatment decisions, so outcomes gaps in HF-CS can be understood and eliminated. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Modes of Death in Patients with Cardiogenic Shock in the Cardiac Intensive Care Unit: A Report from the Critical Care Cardiology Trials Network

Author

Berg, David D., primary, Singal, Sachit, additional, Palazzolo, Michael, additional, Baird-Zars, Vivian M., additional, Bofarrag, Fadel, additional, Bohula, Erin A., additional, Chaudhry, Sunit-Preet, additional, Dodson, Mark W., additional, Hillerson, Dustin, additional, Lawler, Patrick R., additional, Liu, Shuangbo, additional, O'Brien, Connor G., additional, Pisani, Barbara A., additional, Racharla, Lekha, additional, Rowsell, Robert O., additional, Shah, Kevin S., additional, Solomon, Michael A., additional, Sridharan, Lakshmi, additional, Thompson, Andrea D., additional, Diepen, Sean van, additional, Katz, Jason N., additional, and Morrow, David A., additional

Published
2024
Full Text
View/download PDF

16. De Novo vs Acute-on-Chronic Presentations of Heart Failure-Related Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry

Author

Bhatt, Ankeet S., Berg, David D., Bohula, Erin A., Alviar, Carlos L., Baird-Zars, Vivian M., Barnett, Christopher F., Burke, James A., Carnicelli, Anthony P., Chaudhry, Sunit-Preet, Daniels, Lori B., Fang, James C., Fordyce, Christopher B., Gerber, Daniel A., Guo, Jianping, Jentzer, Jacob C., Katz, Jason N., Keller, Norma, Kontos, Michael C., Lawler, Patrick R., Menon, Venu, Metkus, Thomas S., Nativi-Nicolau, Jose, Phreaner, Nicholas, Roswell, Robert O., Sinha, Shashank S., Jeffrey Snell, R., Solomon, Michael A., Van Diepen, Sean, and Morrow, David A.

Published
2021
Full Text
View/download PDF

17. Management and Outcomes of Cardiogenic Shock in Cardiac ICUs With Versus Without Shock Teams

Author

Papolos, Alexander I., Kenigsberg, Benjamin B., Berg, David D., Alviar, Carlos L., Bohula, Erin, Burke, James A., Carnicelli, Anthony P., Chaudhry, Sunit-Preet, Drakos, Stavros, Gerber, Daniel A., Guo, Jianping, Horowitz, James M., Katz, Jason N., Keeley, Ellen C., Metkus, Thomas S., Nativi-Nicolau, Jose, Snell, Jeffrey R., Sinha, Shashank S., Tymchak, Wayne J., Van Diepen, Sean, Morrow, David A., and Barnett, Christopher F.

Published
2021
Full Text
View/download PDF

22. Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61

Author

Patel, Siddharth M., primary, Morrow, David A., additional, Bellavia, Andrea, additional, Berg, David D., additional, Bhatt, Deepak L., additional, Jarolim, Petr, additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Raz, Itamar, additional, Steg, P. Gabriel, additional, Wilding, John P. H., additional, Sabatine, Marc S., additional, Wiviott, Stephen D., additional, Braunwald, Eugene, additional, Scirica, Benjamin M., additional, and Bohula, Erin A., additional

Published
2023
Full Text
View/download PDF

24. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial

Author

Berg, David D., Docherty, Kieran F., Sattar, Naveed, Jarolim, Petr, Welsh, Paul, Jhund, Pardeep S., Anand, Inder S., Chopra, Vijay, de Boer, Rudolf A., Kosiborod, Mikhail N., Nicolau, Jose C., O’Meara, Eileen, Schou, Morten, Hammarstedt, Ann, Langkilde, Anna-Maria, Lindholm, Daniel, Sjöstrand, Mikaela, McMurray, John J.V., Sabatine, Marc S., and Morrow, David A.

Published
2022
Full Text
View/download PDF

25. Need for a Cardiogenic Shock Team Collaborative--Promoting a Team-Based Model of Care to Improve Outcomes and Identify Best Practices.

Author

Senman, Balimkiz, Jentzer, Jacob C., Barnett, Christopher F., Bartos, Jason A., Berg, David D., Chih, Sharon, Drakos, Stavros G., Dudzinski, David M., Elliott, Andrea, Gage, Ann, Horowitz, James M., Miller, P. Elliott, Sinha, Shashank S., Tehrani, Behnam N., Yuriditsky, Eugene, Vallabhajosyula, Saraschandra, and Katz, Jason N.

Published
2024
Full Text
View/download PDF

26. Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61.

Author

Patel, Siddharth M., Morrow, David A., Bellavia, Andrea, Berg, David D., Bhatt, Deepak L., Jarolim, Petr, Leiter, Lawrence A., McGuire, Darren K., Raz, Itamar, Steg, P. Gabriel, Wilding, John P.H., Sabatine, Marc S., Wiviott, Stephen D., Braunwald, Eugene, Scirica, Benjamin M., and Bohula, Erin A.

Subjects
DAPAGLIFLOZIN, BRAIN natriuretic factor, NATRIURETIC peptides, BODY mass index, HEART failure, HEART metabolism disorders, RISK assessment
Abstract

Aim: N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) concentrations are lower in patients with obesity. The interaction between body mass index (BMI) and NT‐proBNP with respect to heart failure risk remains incompletely defined. Methods and results: Data were pooled across three randomized clinical trials enrolling predominantly patients who were overweight or obese with established cardiometabolic disease: SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61. Hospitalization for heart failure (HHF) was examined across strata of baseline BMI and NT‐proBNP. The effect of dapagliflozin versus placebo was assessed for a treatment interaction across BMI categories in patients with or without an elevated baseline NT‐proBNP (≥125 pg/ml). Among 24 455 patients, the median NT‐proBNP was 96 (interquartile range [IQR]: 43–225) pg/ml and the median BMI was 33 (IQR 29–37) kg/m2, with 68% of patients having a BMI ≥30 kg/m2. There was a significant inverse association between NT‐proBNP and BMI which persisted after adjustment for all clinical variables (p < 0.001). Within any range of NT‐proBNP, those at higher BMI had higher risk of HHF at 2 years (comparing BMI <30 vs. ≥40 kg/m2 for NT‐proBNP ranges of <125, 125–<450 and ≥450 pg/ml: 0.0% vs. 0.6%, 1.3% vs. 4.0%, and 8.1% vs. 13.8%, respectively), which persisted after multivariable adjustment (adjusted hazard ratio [HRadj] 7.47, 95% confidence interval [CI] 3.16–17.66, HRadj 3.22 [95% CI 2.13–4.86], and HRadj 1.87 [95% CI 1.35–2.60], respectively). In DECLARE‐TIMI 58, dapagliflozin versus placebo consistently reduced HHF across BMI categories in those with an elevated NT‐proBNP (p‐trend for HR across BMI = 0.60), with a pattern of greater absolute risk reduction (ARR) at higher BMI (ARR for BMI <30 to ≥40 kg/m2: 2.2% to 4.7%; p‐trend = 0.059). Conclusions: The risk of HHF varies across BMI categories for any given range of circulating NT‐proBNP. These findings showcase the importance of considering BMI when applying NT‐proBNP for heart failure risk stratification, particularly for patients with low‐level elevations in NT‐proBNP (125–<450 pg/ml) where there appears to be a clinically meaningful absolute and relative risk gradient. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Prognostic significance of haemodynamic parameters in patients with cardiogenic shock

Author

Berg, David D, primary, Kaur, Gurleen, additional, Bohula, Erin A, additional, Baird-Zars, Vivian M, additional, Alviar, Carlos L, additional, Barnett, Christopher F, additional, Barsness, Gregory W, additional, Burke, James A, additional, Chaudhry, Sunit-Preet, additional, Chonde, Meshe, additional, Cooper, Howard A, additional, Daniels, Lori B, additional, Dodson, Mark W, additional, Gerber, Daniel A, additional, Ghafghazi, Shahab, additional, Gidwani, Umesh K, additional, Goldfarb, Michael J, additional, Guo, Jianping, additional, Hillerson, Dustin, additional, Kenigsberg, Benjamin B, additional, Kochar, Ajar, additional, Kontos, Michael C, additional, Kwon, Younghoon, additional, Lopes, Mathew S, additional, Loriaux, Daniel B, additional, Miller, P Elliott, additional, O’Brien, Connor G, additional, Papolos, Alexander I, additional, Patel, Siddharth M, additional, Pisani, Barbara A, additional, Potter, Brian J, additional, Prasad, Rajnish, additional, Rowsell, Robert O, additional, Shah, Kevin S, additional, Sinha, Shashank S, additional, Smith, Timothy D, additional, Solomon, Michael A, additional, Teuteberg, Jeffrey J, additional, Thompson, Andrea D, additional, Zakaria, Sammy, additional, Katz, Jason N, additional, van Diepen, Sean, additional, and Morrow, David A, additional

Published
2023
Full Text
View/download PDF

29. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 inhibition in Patients with Type 2 Diabetes

Author

Moura, Filipe A., primary, Berg, David D., primary, Bellavia, Andrea, primary, Dwyer, Jamie P., primary, Mosenzon, Ofri, primary, A. Scirica, Benjamin, primary, Wiviott, Stephen D., primary, Bhatt, Deepak L., primary, Raz, Itamar, primary, Feinberg, Mark W., primary, Braunwald, Eugene, primary, Morrow, David A., primary, and Sabatine, Marc S., primary

Published
2023
Full Text
View/download PDF

34. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure

Author

Docherty, Kieran F., primary, McDowell, Kirsty, additional, Welsh, Paul, additional, Osmanska, Joanna, additional, Anand, Inder, additional, de Boer, Rudolf A., additional, Køber, Lars, additional, Kosiborod, Mikhail N., additional, Martinez, Felipe A., additional, O’Meara, Eileen, additional, Ponikowski, Piotr, additional, Schou, Morten, additional, Berg, David D., additional, Sabatine, Marc S., additional, Morrow, David A., additional, Jarolim, Petr, additional, Hammarstedt, Ann, additional, Sjöstrand, Mikaela, additional, Langkilde, Anna Maria, additional, Solomon, Scott D., additional, Sattar, Naveed, additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

35. Abstract 15559: In-hospital versus Out-of-hospital Cardiac Arrest in Patients Presenting to Cardiac Intensive Care Units: From the Critical Care Cardiology Trials Network (CCCTN) Registry

Author

CARNICELLI, Anthony P, Brown, Kelly, Guo, Jianping, Kendsersky, Payton, Arps, Kelly E, Dixson, Jeffrey A, Keane, Ryan, Berg, David D, Bohula, Erin A, Harrison, Robert W, Granger, Christopher B, Van Diepen, Sean, Morrow, David A, Katz, Jason N, and Newby, L. Kristin

Published
2020
Full Text
View/download PDF

39. Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center

Author

Eberly, Lauren A., Richterman, Aaron, Beckett, Anne G., Wispelwey, Bram, Marsh, Regan H., Cleveland Manchanda, Emily C., Chang, Cindy Y., Glynn, Robert J., Brooks, Katherine C., Boxer, Robert, Kakoza, Rose, Goldsmith, Jennifer, Loscalzo, Joseph, Morse, Michelle, Lewis, Eldrin F., Abel, Samantha, Adams, Ayrenne, Anaya, Joseph, Andrews, Erik H, Atkinson, Benjamin, Avutu, Viswatej, Bachorik, Alexandra, Badri, Omar, Bailey, Mariel, Baird, Katie, Bakshi, Salina, Balaban, Denis, Barshop, Kenneth, Baumrin, Emily, Bayomy, Omar, Beamesderfer, Julia, Becker, Nora, Berg, David D., Berman, Adam N., Blum, Steven M., Boardman, Alexander P., Boden, Kaeleen, Bonacci, Robert A, Brown, Sarah, Campbell, Kirsti, Case, Siobhan, Cetrone, Emily, Charrow, Alexandra, Chiang, David, Clark, Devin, Cohen, Aaron J., Cooper, Alissa, Cordova, Tomas, Cuneo, C. Nicholas, de Feria, Alsina Alejandro, Deffenbacher, Karen, DeFilippis, Ersilia M., DeGregorio, Geneva, Deutsch, Aaron J., Diephuis, Bradford, Divakaran, Sanjay, Dorschner, Peter, Downing, Nicholas, Drescher, Caitlin, D’Silva, Kristin M., Dunbar, Peter, Duong, David, Earp, Sarah, Eckhardt, Christine, Elman, Scott A., England, Ross, Everett, Kay, Fedotova, Natalie, Feingold-Link, Tamara, Ferreira, Mark, Fisher, Herrick, Foo, Patricia, Foote, Michael, Franco, Idalid, Gilliland, Thomas, Greb, Jacqueline, Greco, Katherine, Grewal, Sungat, Grin, Benjamin, Growdon, Matthew E., Guercio, Brendan, Hahn, Cynthia K., Hasselfeld, Brian, Haydu, Erika J, Hermes, Zachary, Hildick-Smith, Gordon, Holcomb, Zachary, Holroyd, Kathryn, Horton, Laura, Huang, George, Jablonski, Stanley, Jacobs, Douglas, Jain, Nina, Japa, Sohan, Joseph, Richard, Kalashnikova, Mariya, Kalwani, Neil, Kang, Daniel, Karan, Abraar, Katz, Joel T, Kellner, Daniel, Kidia, Khameer, Kim, June-Ho, Knowles, Scott M, Kolbe, Laura, Kore, Idil, Koullias, Yiannis, Kuye, Ifedayo, Lang, Joshua, Lawlor, Matthew, Lechner, Melissa G., Lee, Ken, Lee, Scott, Lee, Zachary, Limaye, Neha, Lin-Beckford, Stephanie, Lipsyc, Marla, Little, Jessica, Loewenthal, Julia, Logaraj, Ranjani, Lopez, Diana M, Loriaux, Daniel, Lu, Yi, Ma, Kevin, Marukian, Nareh, Matias, Wilfredo, Mayers, Jared R., McConnell, Ian, McLaughlin, Michael, Meade, Christina, Meador, Catherine, Mehta, Anish, Messenger, Elizabeth, Michaelidis, Constantinos, Mirsky, Jacob, Mitten, Emilie, Mueller, Alisa, Mullur, Jyotsna, Munir, Amir, Murphy, Emily, Nagami, Ellen, Natarajan, Abirami, Nsahlai, Michelle, Nze, Chijioke, Okwara, Noreen, Olds, Peter, Paez, Rafael, Pardo, Michael, Patel, Siddharth, Petersen, Alec, Phelan, Laura, Pimenta, Erica, Pipilas, Daniel, Plovanich, Molly, Pong, Denise, Powers, Brian W., Rao, Anita, Ramirez Batlle, Haiyan, Ramsis, Mattheus, Reichardt, Anna, Reiger, Sheridan, Rengarajan, Michelle, Rico, Stephanie, Rome, Benjamin N., Rosales, Rachael, Rotenstein, Lisa, Roy, Alexis, Royston, Sarah, Rozansky, Hallie, Rudder, Meghan, Ryan, Christine E., Salgado, Sanjay, Sanchez, Pablo, Schulte, Jennifer, Sekar, Aswin, Semenkovich, Nicholas, Shannon, Evan, Shaw, Neil, Shorten, Andrew Ben, Shrauner, William, Sinnenberg, Lauren, Smithy, James W., Snyder, Gregory, Sreekrishnan, Anirudh, Stabenau, Hans, Stavrou, Eleni, Stergachis, Andrew, Stern, Robert, Stone, Alexander, Tabrizi, Shervin, Tanyos, Sam, Thomas, Cristina, Thun, Haley, Torres-Lockhart, Kristine, Tran, An, Treasure, Carolyn, Tsai, Frederick D., Tsaur, Stephen, Tschirhart, Evan, Tuwatananurak, Justin, Venkateswaran, Ramkumar V., Vishnevetsky, Anastasia, Wahl, Lindsay, Wall, April, Wallace, Frances, Walsh, Elisa, Wang, Priscilla, Ward, Heather B., Warner, Lindsay N., Weeks, Lachelle D., Weiskopf, Kipp, Wengrod, Jordan, Williams, Jessica N., Winkler, Marisa, Wong, Jeffrey L., Worster, Devin, Wright, Aileen, Wunsch, Caroline, Wynter, Jamila S., Yarbrough, Chase, Yau, Wai-Ying, Yazdi, Daniel, Yeh, Jennifer, Yialamas, Maria A., Yozamp, Nicholas, Zambrotta, Marina, and Zon, Rebecca

Published
2019
Full Text
View/download PDF

40. Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry

Author

Berg, David D., Barnett, Christopher F., Kenigsberg, Benjamin B., Papolos, Alexander, Alviar, Carlos L., Baird-Zars, Vivian M., Barsness, Gregory W., Bohula, Erin A., Brennan, Joseph, Burke, James A., Carnicelli, Anthony P., Chaudhry, Sunit-Preet, Cremer, Paul C., Daniels, Lori B., DeFilippis, Andrew P., Gerber, Daniel A., Granger, Christopher B., Hollenberg, Steven, Horowitz, James M., Gladden, James D., Katz, Jason N., Keeley, Ellen C., Keller, Norma, Kontos, Michael C., Lawler, Patrick R., Menon, Venu, Metkus, Thomas S., Miller, P. Elliott, Nativi-Nicolau, Jose, Newby, L. Kristin, Park, Jeong-Gun, Phreaner, Nicholas, Roswell, Robert O., Schulman, Steven P., Sinha, Shashank S., Snell, R. Jeffrey, Solomon, Michael A., Teuteberg, Jeffrey J., Tymchak, Wayne, van Diepen, Sean, and Morrow, David A.

Published
2019
Full Text
View/download PDF

43. Characteristics, therapies, and outcomes of In-Hospital vs Out-of-Hospital cardiac arrest in patients presenting to cardiac intensive care units: From the critical care Cardiology trials network (CCCTN)

Author

Carnicelli, Anthony P, primary, Keane, Ryan, additional, Brown, Kelly M, additional, Loriaux, Daniel B, additional, Kendsersky, Payton, additional, Alviar, Carlos L, additional, Arps, Kelly, additional, Berg, David D, additional, Bohula, Erin A, additional, Burke, James A, additional, Dixson, Jeffrey A, additional, Gerber, Daniel A, additional, Goldfarb, Michael, additional, Granger, Christopher B, additional, Guo, Jianping, additional, Harrison, Robert W, additional, Kontos, Michael, additional, Lawler, Patrick R, additional, Miller, P Elliott, additional, Nativi-Nicolau, Jose, additional, Newby, L Kristin, additional, Racharla, Lekha, additional, Roswell, Robert O, additional, Shah, Kevin S, additional, Sinha, Shashank S, additional, Solomon, Michael A, additional, Teuteberg, Jeffrey, additional, Wong, Graham, additional, van Diepen, Sean, additional, Katz, Jason N, additional, and Morrow, David A, additional

Published
2023
Full Text
View/download PDF

44. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure

Author

Docherty, Kieran F., McDowell, Kirsty, Welsh, Paul, Osmanska, Joanna, Anand, Inder, de Boer, Rudolf A., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., O'Meara, Eileen, Ponikowski, Piotr, Schou, Morten, Berg, David D., Sabatine, Marc S., Morrow, David A., Jarolim, Petr, Hammarstedt, Ann, Sjöstrand, Mikaela, Langkilde, Anna Maria, Solomon, Scott D., Sattar, Naveed, Jhund, Pardeep S., McMurray, John J. V., Docherty, Kieran F., McDowell, Kirsty, Welsh, Paul, Osmanska, Joanna, Anand, Inder, de Boer, Rudolf A., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., O'Meara, Eileen, Ponikowski, Piotr, Schou, Morten, Berg, David D., Sabatine, Marc S., Morrow, David A., Jarolim, Petr, Hammarstedt, Ann, Sjöstrand, Mikaela, Langkilde, Anna Maria, Solomon, Scott D., Sattar, Naveed, Jhund, Pardeep S., and McMurray, John J. V.

Abstract

Background: Elevated circulating carbohydrate antigen 125 (CA125) is a marker of congestion and a predictor of outcomes in acute heart failure (HF). Less is known about CA125 in chronic ambulatory HF with reduced ejection fraction. Objectives: This study examined the association between baseline CA125 (and changes in CA125) and outcomes in patients with HF with reduced ejection fraction in the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; NCT03036124) trial and its relationship with the effect of dapagliflozin. Methods: The primary outcome was a composite of a first episode of worsening HF or cardiovascular death. CA125 was measured at baseline and 12 months following randomization. Results: Median baseline CA125 was 13.04 U/mL (IQR: 8.78-21.13 U/mL) in 3,123 of 4,774 patients with available data. Compared with CA125 ≤35 U/mL (upper limit of normal), patients with CA125 >35 U/mL were at a higher risk of the primary outcome (adjusted HR: 1.59; 95% CI: 1.29-1.96). The adjusted risks of the primary outcome relative to quartile 1 (Q1) (≤8.78 U/mL) were as follow: Q2, 8.79-13.04 U/mL (HR: 0.94; 95% CI: 0.71-1.24); Q3, 13.05-21.13 U/mL (HR: 1.22; 95% CI: 0.94-1.59); Q4, ≥21.14 U/mL (HR: 1.63; 95% CI: 1.28-2.09). The beneficial effect of dapagliflozin compared with placebo on the primary outcome was consistent whether CA125 was analyzed in quartiles (interaction P = 0.13) or as a continuous variable (interaction P = 0.75). The placebo-corrected relative change in CA125 at 12 months was −5.2% (95% CI: −10.6% to 0.5%; P = 0.07). Conclusions: In DAPA-HF, elevated CA125 levels were an independent predictor of the risk of worsening HF or cardiovascular death. Dapagliflozin reduced the risk of worsening HF or cardiovascular death regardless of baseline CA125.

Published
2023

46. Epidemiology of Shock in Contemporary Cardiac Intensive Care Units: Data From the Critical Care Cardiology Trials Network Registry

Author

Berg, David D., Bohula, Erin A., van Diepen, Sean, Katz, Jason N., Alviar, Carlos L., Baird-Zars, Vivian M., Barnett, Christopher F., Barsness, Gregory W., Burke, James A., Cremer, Paul C., Cruz, Jennifer, Daniels, Lori B., DeFilippis, Andrew P., Haleem, Affan, Hollenberg, Steven M., Horowitz, James M., Keller, Norma, Kontos, Michael C., Lawler, Patrick R., Menon, Venu, Metkus, Thomas S., Ng, Jason, Orgel, Ryan, Overgaard, Christopher B., Park, Jeong-Gun, Phreaner, Nicholas, Roswell, Robert O., Schulman, Steven P., Jeffrey Snell, R., Solomon, Michael A., Ternus, Bradley, Tymchak, Wayne, Vikram, Fnu, and Morrow, David A.

Published
2019
Full Text
View/download PDF

48. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes.

Author

Moura, Filipe A., Berg, David D., Bellavia, Andrea, Dwyer, Jamie P., Mosenzon, Ofri, Scirica, Benjamin M., Wiviott, Stephen D., Bhatt, Deepak L., Raz, Itamar, Feinberg, Mark W., Braunwald, Eugene, Morrow, David A., and Sabatine, Marc S.

Subjects
*DISEASE risk factors, *DAPAGLIFLOZIN, *CANAGLIFLOZIN, *TYPE 2 diabetes, *DISEASE progression, *CHRONIC kidney failure, *SYSTOLIC blood pressure
Abstract

OBJECTIVE: To develop a risk assessment tool to identify patients with type 2 diabetes (T2D) at higher risk for kidney disease progression and who might benefit more from sodium–glucose cotransporter 2 (SGLT2) inhibition. RESEARCH DESIGN AND METHODS: A total of 41,204 patients with T2D from four Thrombolysis In Myocardial Infarction (TIMI) clinical trials were divided into derivation (70%) and validation cohorts (30%). Candidate predictors of kidney disease progression (composite of sustained ≥40% decline in estimated glomerular filtration rate [eGFR], end-stage kidney disease, or kidney death) were selected with multivariable Cox regression. Efficacy of dapagliflozin was assessed by risk categories (low: <0.5%; intermediate: 0.5 to <2%; high: ≥2%) in Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58. RESULTS: There were 695 events over a median follow-up of 2.4 years. The final model comprised eight independent predictors of kidney disease progression: atherosclerotic cardiovascular disease, heart failure, systolic blood pressure, T2D duration, glycated hemoglobin, eGFR, urine albumin-to-creatinine ratio, and hemoglobin. The c-indices were 0.798 (95% CI, 0.774–0.821) and 0.798 (95% CI, 0.765–0.831) in the derivation and validation cohort, respectively. The calibration plot slope (deciles of predicted vs. observed risk) was 0.98 (95% CI, 0.93–1.04) in the validation cohort. Whereas relative risk reductions with dapagliflozin did not differ across risk categories, there was greater absolute risk reduction in patients with higher baseline risk, with a 3.5% absolute risk reduction in kidney disease progression at 4 years in the highest risk group (≥1%/year). Results were similar with the 2022 Chronic Kidney Disease Prognosis Consortium risk prediction model. CONCLUSIONS: Risk models for kidney disease progression can be applied in patients with T2D to stratify risk and identify those who experience a greater magnitude of benefit from SGLT2 inhibition. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results